Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma
Authors:
- 15 March 2017
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 31 (6) , 1463-1466
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2014
- International Myeloma Working Group recommendations for global myeloma careLeukemia, 2013
- Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialBlood, 2013
- Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaLeukemia, 2013
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 TrialJournal of Clinical Oncology, 2012
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaBlood, 2012
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pBlood, 2012
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyThe Lancet Oncology, 2011
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasoneLeukemia, 2010
- International uniform response criteria for multiple myelomaLeukemia, 2006